Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Carcinoma, Non-Small Cell Lung: early-phase trial registry
43 of 133 indexed Carcinoma, Non-Small Cell Lung trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #86 of 28,707 conditions by registered trial count.
133 US clinical trials · 43 currently recruiting · #86 of 28,707 conditions by registered trial count
Carcinoma, Non-Small Cell Lung: 133 US clinical trials tracked, 43 recruiting.
Carcinoma, Non-Small Cell Lung is the subject of 133 registered US clinical trials on ClinicalTrials.gov, 43 of them currently open to new participants. 27 are in Phase 3-4 (later-stage) and 92 in Phase 1-2 (earlier-stage). The most active sponsor is Pfizer, running 14 of these trials.
Enrollment posture brief
Registry condition carcinoma-non-small-cell-lung
OPEN 43 | RECR 32% | LATE 27 | EARLY 92 | RANK #86 | SPON 14
Volume-matched condition peers
Nearest open-share peer: Anatomic Stage IIIB Breast Cancer AJCC v8 (32% recruiting · 34 trials)
Carcinoma, Non-Small Cell Lung lists 43 open slots (32% of 133 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Carcinoma, Non-Small Cell Lung on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Carcinoma, Non-Small Cell Lung is recruiting below its size-band peers.
43 of 133 indexed trials (32.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Carcinoma, Non-Small Cell Lung trials is spread across many organizations.
Pfizer accounts for 14 of 133 trials (10.5%). 59 distinct sponsors appear on at least one study for this condition label.
-
Typical Carcinoma, Non-Small Cell Lung enrolment sits around 126 participants.
Median target enrolment is 126 among the 131 trials that report a genuine target (sentinel values excluded). 58 of those (44.3%) plan for fewer than 100 participants.
-
Carcinoma, Non-Small Cell Lung research is mostly interventional.
123 interventional and 10 observational studies make up this index (92.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
133 total, page 1 of 3
MYLUNG Consortium Part 3: Observational Study
US Oncology Research
NCT05885698
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Pfizer
NCT07222566
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Eli Lilly and Company
NCT06119581
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
Merck Sharp & Dohme
NCT04165798
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT04389632
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT06131840
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
AstraZeneca
NCT06868277
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT05208762
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Pfizer
NCT06758401
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Eli Lilly and Company
NCT06890598
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Merck Sharp & Dohme
NCT06623422
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Mirati Therapeutics
NCT06875310
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Eli Lilly and Company
NCT04956640
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Janssen Research & Development
NCT05498428
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Eli Lilly and Company
NCT06400472
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Janssen Research & Development
NCT06667076
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Merck Sharp & Dohme
NCT04165070
First in Human Study of AZD9592 in Solid Tumors
AstraZeneca
NCT05647122
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Pfizer
NCT06447662
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Pfizer
NCT07090499
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
Janssen Research & Development
NCT06120140
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
AstraZeneca
NCT06008093
A Study of LY4175408 in Participants With Advanced Cancer
Eli Lilly and Company
NCT07046923
Confocal Laser Endomicroscopy VERification
Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)
NCT06079970
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
Travera
NCT05461430
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Pfizer
NCT07227298
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
Genprex
NCT04486833
A Study of DM005 in Patients With Advanced Solid Tumors
Doma Biopharmaceutical（Suzhou）Co.
NCT06515990
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Johnson & Johnson Enterprise Innovation
NCT06667908
A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)
Bristol-Myers Squibb
NCT06855771
A Study of DM001 in Patients With Advanced Solid Tumors
Xadcera Biopharmaceutical (Suzhou) Co.
NCT06475937
A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
Johnson & Johnson Enterprise Innovation
NCT06116786
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
Weill Medical College of Cornell University
NCT06623656
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
Hackensack Meridian Health
NCT05715229
Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.
University of Colorado, Denver
NCT03958565
Development and Analysis of a Stool Bank for Cancer Patients
Persephone Biosciences
NCT04291755
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
Merck Sharp & Dohme
NCT06780085
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Lantern Pharma
NCT05456256
Patient-centered, Optimal Integration of Survivorship and Palliative Care
Massachusetts General Hospital
NCT04900935
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
Janssen Research & Development
NCT07227025
Osimertinib In EGFR Mutant Lung Cancer
Dana-Farber Cancer Institute
NCT03586453
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
Georgetown University
NCT04499053
Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer
The Methodist Hospital Research Institute
NCT06566443
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Janssen Research & Development
NCT04487080
MYLUNG Consortium Study Protocol 2
US Oncology Research
NCT05644808
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
Merck Sharp & Dohme
NCT04380636
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
Janssen Research & Development
NCT04988295
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
AstraZeneca
NCT03833154
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
Seagen, a wholly owned subsidiary of Pfizer
NCT06012435
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
Janssen Research & Development
NCT04077463
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 58 |
| Phase 2 | 34 |
| Phase 3 | 27 |
Top Sponsors
Named interventions
Most-linked intervention names on Carcinoma, Non-Small Cell Lung records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Carcinoma, Non-Small Cell Lung trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Carcinoma, Non-Small Cell Lung page
133 registered trials, 43 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 43 Carcinoma, Non-Small Cell Lung trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Pfizer sponsors the most Carcinoma, Non-Small Cell Lung trials on record, review their full trial history before evaluating a specific study. See Pfizer's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Carcinoma, Non-Small Cell Lung condition card totals 133 registered trials; most-linked intervention Carboplatin; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.